STAT reports that Vertex’s kidney disease drug is being closely examined for infection risk as the FDA prepares to make an approval decision on 30 November. The scrutiny reflects regulatory attention to safety concerns in new therapies, especially for high-risk patient groups.
For pharma executives, this signals the importance of addressing safety data in regulatory submissions and market planning. The FDA’s approach may influence how similar drugs are evaluated and could shape future approval timelines and requirements.
